Lanvis is a medicine containing the active ingredient(s) tioguanine. On this page you will find out more about Lanvis, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: tioguanine
Information for medicine and pack size:
Lanvis 40 mg uncoated tablet, 25
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
INDICATIONS AS AT 10 OCTOBER 2005: Acute myeloblastic leukaemia. Less commonly, chronic granulocytic (myelocytic, myeloid, myelogenous) leukaemia. Although superior results are generally obtained with busulphan (Myleran) in the treatment of chronic granulocytic leukaemia. LANVIS may be useful during blast crises or periods of thrombocytopenia induced by busulphan or other therapy. A degree of cross resistance exists between LANVIS (thioguanine) and Puri-Nethol (mercaptopurine) and generally it is not to be expected that patients who no longer respond to mercaptopurine will respond to thioguanine or vice versa. Unlike mercaptopurine the detoxification of LANVIS is not dependent on xanthine oxidase, hence therapy with LANVIS is not affected by the xanthine oxidase inhibitor, allopurinol (Zyloprim). Recent evidence suggests that LANVIS is particularly useful in concurrent or sequelist combination with other antineoplastic drugs, e.g., cytosine arabinoside. Not effective for the treatment of chronic lymphocytic leukaemia or solid tumours. The aim of therapy is to achieve normal appearance of the bone marrow and pheripheral blood. It is recognised, however, that in treating acute leukaemia, one may not always be able to achieve complete remissions and must be satisfied with partial improvement.
Table of characteristics
White to off-white tablet, round, biconvex scored and marked "T40" on one side and plain on the other
Images are the copyright of the Pharmacy Guild of Australia
|Dosage Form||Tablet, uncoated|
|Route of administration||Oral|
25 tablets: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||Store in a Dry Place,Protect from Light|
|Life time||4 Years|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 May 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.